Clinical studies have also shown efficacy for other orally administered PDE4 selective inhibitors on relevant asthma endpoints such as inhibition of allergen challenge[9, 10] and exercise induced bronchoconstriction[11], as well as improvements in lung function[12]. This evidence concerns the gene PDE4A and asthma.